Summary of Thalidomide
This week, we explored Thalidomide, an Immunomodulatory Drug (IMiD) with a remarkable medical history. Once withdrawn due to its severe teratogenic effects, it is now used under strict safety programs for specific conditions.
Mechanism of Action (MOA)
• Modulates the immune system by reducing the production of Tumor Necrosis Factor-alpha (TNF-α)
• Inhibits angiogenesis (formation of new blood vessels)
• Enhances T-cell and Natural Killer (NK) cell activity
• Induces apoptosis of malignant plasma cells in multiple myeloma
Clinical Uses
• Multiple Myeloma (in combination with other anticancer agents)
• Erythema Nodosum Leprosum (ENL) associated with leprosy
• Selected inflammatory and autoimmune disorders (under specialist supervision)
Role in Multiple Myeloma
By its immunomodulatory and anti-angiogenic effects, Thalidomide helps:
• Suppress the growth of myeloma cells
• Reduce blood vessel formation that supports tumor growth
• Enhance immune-mediated destruction of cancer cells
• Improve treatment outcomes when combined with other therapies
Common Adverse Effects
• Drowsiness and sedation
• Constipation
• Dizziness
• Peripheral neuropathy (tingling or numbness in hands and feet)
• Skin rash
Contraindications
• Pregnancy or planning pregnancy
• Women of childbearing potential not using effective contraception
• Hypersensitivity to Thalidomide
• Caution in patients with pre-existing peripheral neuropathy or high risk of thrombosis
Clinical pearl
Thalidomide is one of the most important examples of why drug safety, pharmacovigilance, and pregnancy risk assessment are essential in clinical practice. Despite its tragic history, strict prescribing programs have transformed it into a valuable treatment for multiple myeloma and erythema nodosum leprosum.
MBH/PS